BioCentury | Dec 20, 2010
Clinical News

ABT-806: Phase I started

...Abbott began a 6-month, open-label, dose-ranging Phase I trial to evaluate IV ABT-806 in up to...
...Science Pharmaceuticals Inc. , Greenwich, Conn. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: ABT-806 (formerly mAb806...
BioCentury | Nov 24, 2008
Company News

Life Science Pharmaceuticals, Abbott deal

...Life Science granted Abbott exclusive, worldwide rights to develop and commercialize ch806 to treat cancer and...
BioCentury | Mar 12, 2007
Clinical News

Ch806: Phase I data

...In a dose-escalation, Australian Phase I trial in 8 cancer patients, ch806 showed tumor-specific targeting with...
...Proceedings of the National Academy of Sciences. Life Science Pharmaceuticals Inc. , Greenwich, Conn. Product: Ch806...
Items per page:
1 - 3 of 3